Targeted Therapy in Advanced Melanoma With Rare
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Melanoma
/ drug therapy
Middle Aged
Molecular Targeted Therapy
Mutation
Progression-Free Survival
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Retrospective Studies
Skin Neoplasms
/ drug therapy
Survival Rate
Translocation, Genetic
Young Adult
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 11 2019
20 11 2019
Historique:
pubmed:
4
10
2019
medline:
27
6
2020
entrez:
4
10
2019
Statut:
ppublish
Résumé
BRAF/MEK inhibition is a standard of care for patients with In the current study, 103 patients with metastatic melanoma with rare, activating non-V600E/K Fifty-eight patient tumors (56%) harbored a non-E/K V600 mutation, 38 (37%) a non-V600 mutation, and seven had both V600E and a rare Patients with rare
Identifiants
pubmed: 31580757
doi: 10.1200/JCO.19.00489
pmc: PMC10448865
doi:
Substances chimiques
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3142-3151Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Références
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32913998
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Pathology. 2016 Feb;48(2):188-93
pubmed: 27020391
Eur J Cancer. 2013 Mar;49(5):1073-9
pubmed: 23237741
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
Melanoma Res. 2014 Oct;24(5):504-8
pubmed: 24933606
Br J Dermatol. 2017 Oct;177(4):936-944
pubmed: 28278349
Eur J Cancer. 2017 Sep;82:45-55
pubmed: 28648698
Br J Cancer. 2013 May 28;108(10):2164-71
pubmed: 23579220
Clin Cancer Res. 2019 Feb 15;25(4):1272-1279
pubmed: 30630828
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
J Clin Oncol. 2013 Feb 1;31(4):482-9
pubmed: 23248257
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Clin Cancer Res. 2018 Dec 15;24(24):6483-6494
pubmed: 29903896
Eur J Cancer. 2013 May;49(7):1795-6
pubmed: 23473613
Ann Oncol. 2017 Jul 01;28(7):1631-1639
pubmed: 28475671
Clin Cancer Res. 2019 Jan 1;25(1):158-165
pubmed: 30224342
J Clin Oncol. 2013 Jul 1;31(19):e324-6
pubmed: 23715574
Lancet. 2012 May 19;379(9829):1893-901
pubmed: 22608338
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
J Med Case Rep. 2016 Jun 02;10(1):158
pubmed: 27255157
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Pigment Cell Melanoma Res. 2016 Mar;29(2):222-8
pubmed: 26643848
Nature. 2010 Mar 18;464(7287):427-30
pubmed: 20179705
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Cell. 2010 Jan 22;140(2):209-21
pubmed: 20141835
Pathology. 2018 Dec;50(7):703-710
pubmed: 30348504
J Dtsch Dermatol Ges. 2013 Dec;11(12):1198-9
pubmed: 24016000
Cancer Discov. 2012 Sep;2(9):791-7
pubmed: 22798288
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
J Immunother Cancer. 2017 Feb 21;5:8
pubmed: 28239462
Chembiochem. 2018 Sep 17;19(18):1988-1997
pubmed: 29992710
Cancer. 2017 Apr 15;123(8):1372-1381
pubmed: 27911979
Br J Dermatol. 2011 Apr;164(4):776-84
pubmed: 21166657
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Ann Surg Oncol. 2018 Aug;25(8):2105-2110
pubmed: 29850954
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719